肝癌靶向免疫治疗进展及二代测序应用

StephenW

肝癌靶向免疫治疗进展及二代测序应用
范阳 1 , 邓凯歌 1 , 郑昊然 1 , 刘振廷 1 , 郑永昌 2
隶属关系
隶属关系

    1
    北京协和医院肝外科;
    2
    北京协和医院肝外科;电子地址：[email protected]。

    PMID: 35093601 DOI: 10.1016/j.aohep.2022.100677

抽象的

肝细胞癌（HCC）是全球领先的癌症，具有高度的遗传异质性；新一代测序 (NGS) 技术对发现 HCC 的驱动基因和高频突变做出了重大贡献。基因改变的检测可以让我们预测个体的预后和药物不良反应，为 HCC 患者的个性化医疗铺平道路。在这篇综述中，我们总结了 HCC 的常见全身治疗方案以及遗传生物标志物对接受这些治疗的患者预后的预测效果。最后，我们对NGS技术在指导HCC靶向治疗和免疫治疗方面的潜力提出了未来展望。

关键词： 缩写：HCC：肝细胞癌； CCL5：趋化因子配体 5； CRLM：结直肠肝转移； CTLA-4：细胞毒性 T 淋巴细胞相关蛋白 4； DCR：疾病控制率； EGFR：表皮生长因子受体； FGFR：成纤维细胞生长因子受体； FISH：荧光原位杂交； HBV：乙型肝炎病毒； HRR：同源重组修复；肝细胞癌; ICI：免疫检查点抑制剂；干扰素：干扰素； IHC：免疫组织化学； IPM：免疫预后模型； NCCN：国家综合癌症网络； NGS：下一代测序； NSCLC：非小细胞肺癌； ORR：客观有效率； OS：总生存期； PCR：聚合酶链式反应； PD-1：程序性死亡1； PD-L1：程序性死亡配体 1； PDGFR：血小板衍生生长因子受体； PFS：无进展生存时间； PTK：蛋白质酪氨酸激酶； RT-PCR：逆转录聚合酶链反应； RTK：受体酪氨酸蛋白激酶； TCGA：癌症基因组图谱； TKI：酪氨酸激酶抑制剂； TRM：常驻记忆 T 细胞； TTP：进展时间； Treg：调节性 T 细胞； VEGFR：血管内皮生长因子受体； WGS：全基因组测序；生物标志物；基因检测；免疫疗法； mOS：中位总生存期； mPCR：多重聚合酶链式反应；精准医学；靶向治疗； uHCC：不可切除的肝细胞癌。

版权所有 © 2022。Elsevier España, S.L.U. 出版

StephenW

Progress of targeted and immunotherapy for hepatocellular carcinoma and the application of next-generation sequencing
Fan Yang  1 , Kaige Deng  1 , Haoran Zheng  1 , Zhenting Liu  1 , Yongchang Zheng  2
Affiliations
Affiliations

    1
    Department of liver surgery, Peking Union Medical College Hospital, Beijing, China.
    2
    Department of liver surgery, Peking Union Medical College Hospital, Beijing, China. Electronic address: [email protected].

    PMID: 35093601 DOI: 10.1016/j.aohep.2022.100677

Abstract

Hepatocellular carcinoma (HCC), leading cancer worldwide, has a high degree of genetic heterogeneity; next-generation sequencing (NGS) technology has contributed significantly to the discovery of driving genes as well as high-frequency mutations in HCC. The detection of gene alterations may allow us to predict prognosis and adverse drug reactions for individuals, paving the way for personalized medicine in HCC patients. In this review, we summarized the common systemic therapy regimens for HCC and the predictive efficacy of genetic biomarkers on the prognosis of patients under these treatments. Finally, we put forward a future perspective on the potential of NGS technology for the guidance of targeted therapy and immunotherapy in HCC.

Keywords: Abbreviations: HCC: Hepatocellular carcinoma; CCL5: Chemokine ligand 5; CRLM: Colorectal liver metastases; CTLA-4: Cytotoxic T-lymphocyte-associated protein 4; DCR: Disease control rates; EGFR: Epidermal growth factor receptor; FGFR: Fibroblast growth factor receptor; FISH: Fluorescence in situ hybridization; HBV: Hepatitis B virus; HRR: Homologous recombination repair; Hepatocellular carcinoma; ICI: Immune checkpoint inhibitors; IFN: Interferon; IHC: Immunohistochemistry; IPM: Immune prognosis model; NCCN: National Comprehensive Cancer Network; NGS: Next-generation sequencing; NSCLC: Non-small cell lung cancer; ORR: Objective effective rate; OS: Overall survival; PCR: Polymerase chain reaction; PD-1: Programmed death 1; PD-L1: Programmed death ligand 1; PDGFR: Platelet-derived growth factor receptor; PFS: Progression-free survival time; PTK: Protein tyrosine kinases; RT-PCR: Reverse transcription-polymerase chain reaction; RTK: Receptor tyrosine protein kinase; TCGA: The Cancer Genome Atlas; TKI: Tyrosine kinase inhibitor; TRM: Resident memory T cells; TTP: Time to progress; Treg: Regulatory T cells; VEGFR: Vascular endothelial growth factor receptor; WGS: Whole-genome sequencing; biomarker; gene detection; immunotherapy; mOS: Median overall survival; mPCR: Multiplex Polymerase Chain Reaction; precision medicine; targeted therapy; uHCC: unresectable Hepatocellular carcinoma.

Copyright © 2022. Published by Elsevier España, S.L.U.

StephenW

https://www.sciencedirect.com/sc ... 22000199?via%3Dihub